CAS 2023788-19-2 GLP-1 Tirzepatide 5mg 10mg 15mg 20mg 30mg 60mg Vials Tirzepatide Raw Powder CAS 2023788-19-2

Tirzepatide has been shown to help lose weight in overweight patients. Phase 3 clinical trials are currently underway for weight loss in adults who are overweight, obese, or have weight-related health issues. Tirzepatide has received FDA Fast Track designation to speed up its FDA application for treating adults with obesity, or who are overweight with weight-related health conditions.
In the SURMOUNT-1 clinical trial, the average weight loss with tirzepatide after 72 weeks was 15% for the 5mg dose, 19.5% for the 10mg dose, and 20.9% for the 15mg dose.

tirzepatide is a once-weekly glucose-dependent-stimulating polypeptide (GIP, aka: gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist developed by scientists. ChemicalbookGIP and GLP-1 are both hormones secreted by the gut that promote secretion. tirzepatide combines the effects of two -promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

How much weight can you lose in a week with tirzepatide?
Clinical trials have shown that study participants taking a weekly dose of semaglutide had an average reduction in body weight of 5-10 percent.

Description:

Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.

Tirzepatide, also known as LY 3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

Product picture:

Before and after weight loss：

Product Name Tirzepatide
Purity ≥99%
Colour White Powder
CAS NO. 2023788-19-2
Molecular Formula C225H348N48O68
Molecular Weight 4813.527g/mol
Storage Store in cool and dry places, keep away from strong light.

Packing:

10mg/vial 10vials/box

15mg/vial 10vials/box

20mg/vial 10vials/box

30mg/vial 10vials/box

Shipping：